Market Research Reports and Industry Reports

Global Public Health Partnering 2010-2016: Deal trends, players and financials

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Global Public Health Partnering 2010 to 2016 provides the full collection of Public Health disease deals signed between the worlds pharmaceutical and biotechnology companies since 2010.

Trends in Public Health partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Public Health partnering agreement structure
Public Health partnering contract documents
Top Public Health deals by value
Most active Public Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensors product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Public Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Public Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.

Report scope

Global Public Health Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.

Global Public Health Partnering 2010 to 2016 includes:

Trends in Public Health dealmaking in the biopharma industry since 2010
Analysis of Public Health deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Public Health deal contract documents
Comprehensive access to over 3500 Public Health deal records
The leading Public Health deals by value since 2010
Most active Public Health dealmakers since 2010

The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.

In Global Public Health Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Public Health Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 200 public health deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Public Health dealmaking

2.1. Introduction
2.2. Public Health partnering over the years
2.3. Public Health partnering by deal type
2.4. Public Health partnering by industry sector
2.5. Public Health partnering by stage of development
2.6. Public Health partnering by technology type
2.7. Public Health partnering by therapeutic indication

Chapter 3 Financial deal terms for Public Health partnering

3.1. Introduction
3.2. Disclosed financials terms for Public Health partnering
3.3. Public Health partnering headline values
3.4. Public Health deal upfront payments
3.5. Public Health deal milestone payments
3.6. Public Health royalty rates

Chapter 4 Leading Public Health deals and dealmakers

4.1. Introduction
4.2. Most active in Public Health partnering
4.3. List of most active dealmakers in Public Health
4.4. Top Public Health deals by value

Chapter 5 Public Health contract document directory

5.1. Introduction
5.2. Public Health partnering deals where contract document available

Chapter 6 Public Health dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Public Health therapeutic target

Appendices

Appendix 1 Directory of Public Health deals by company A-Z 2010 to 2016
Appendix 2 Directory of Public Health deals by deal type 2010 to 2016
Appendix 3 Directory of Public Health deals by stage of development 2010 to 2016
Appendix 4 Directory of Public Health deals by technology type 2010 to 2016

List Of Figures

Figure 1: Public Health partnering since 2010
Figure 2: Public Health partnering by deal type since 2010
Figure 3: Public Health partnering by industry sector since 2010
Figure 4: Public Health partnering by stage of development since 2010
Figure 5: Public Health partnering by technology type since 2010
Figure 6: Public Health partnering by indication since 2010
Figure 7: Public Health deals with a headline value
Figure 8: Public Health deals with upfront payment values
Figure 9: Public Health deals with milestone payment
Figure 10: Public Health deals with royalty rates
Figure 11: Active Public Health dealmaking activity 2010 to 2016
Figure 12: Top Public Health deals by value since 2010

Global Pressure Homogenizers Market Research Report 2016

2016 Global Pressure Homogenizers Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Pressure Homogenizers industry, focusing on the main regions

USD 2850View Report

Global Mechanical Homogenizers Market Research Report 2016

2016 Global Mechanical Homogenizers Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Mechanical Homogenizers industry, focusing on the main regions

USD 2850View Report

Global Smart Labels Market Research Report 2016

2016 Global Smart Labels Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Smart Labels industry, focusing on the main regions

USD 2850View Report

2016-2021 Europe Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

Complete report $6,900.  DataPack (test volumes, sales forecasts, supplier shares) $4,500.The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK).  Current scientific

USD 6900View Report

2016-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures--France, Germany, Italy, Japan, Spain, UK, US

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition,

USD 9500View Report

2017 US Hepatitis A, B, C, D, E Diagnostics Market: Blood Banks, Commercial Labs, Hospitals, Physician Offices, Public Health Labs--Supplier Shares, Competitive Strategies, Country Market Segment Volume and Sales Forecasts for Immunodiagnostic and NAT Procedures, Innovative Technologies, Instrumentation Review

Complete report $3,900.  DataPack (test volumes, sales forecasts, supplier shares) $2,500.The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis

USD 3900View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Reports Details

Published Date : Nov -0001
No. of Pages :1000
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Wildwood Ventures Ltd.
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment